Literature DB >> 12530537

Characterization of the VPS10 domain of SorLA/LR11 as binding site for the neuropeptide HA.

Julia Lintzel1, Inga Franke, I Björn Riedel, H Chica Schaller, Wolfgang Hampe.   

Abstract

The single transmembrane receptor sorLA/LR11 contains binding domains typical for the low-density lipoprotein receptors and a VPS10 domain which, in the related receptor sortilin, binds the neuropeptide neurotensin. SorLA is synthesized as a proreceptor which is processed to the mature form by a furin-like propeptidase. Endogenous sorLA and its hydra homologue HAB bind the neuropeptide head activator (HA). Transiently expressed partial sorLA constructs were investigated for ligand binding. We found that HA binds with nanomolar affinity to the VPS10 domain. The sorLA propeptide also bound to the VPS10 domain, whereas the receptor-associated protein RAP interacted both with the class A repeats and the VPS10 domain. The sorLA propeptide inhibited binding of HA to full-length sorLA and to the VPS10 domain. It also interfered with binding of HA to hydra HAB, which is taken as evidence for a highly conserved tertiary structure of the VPS10 domains of this receptor in hydra and mammals. The propeptide inhibited HA-stimulated mitosis and proliferation in the human neuroendocrine cell line BON and the neuronal precursor cell line NT2. We conclude that sorLA is necessary for HA signaling and function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530537     DOI: 10.1515/BC.2002.193

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  WNK4 enhances the degradation of NCC through a sortilin-mediated lysosomal pathway.

Authors:  Bo Zhou; Jieqiu Zhuang; Dingying Gu; Hua Wang; Liudmila Cebotaru; William B Guggino; Hui Cai
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

2.  Novel susceptibility loci for Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Future Neurol       Date:  2015-12

3.  LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease.

Authors:  Sara E Dodson; Marla Gearing; Carol F Lippa; Thomas J Montine; Allan I Levey; James J Lah
Journal:  J Neuropathol Exp Neurol       Date:  2006-09       Impact factor: 3.685

4.  Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor.

Authors:  Katrin Boels; H Chica Schaller
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

5.  Coding mutations in SORL1 and Alzheimer disease.

Authors:  Badri N Vardarajan; Yalun Zhang; Joseph H Lee; Rong Cheng; Christopher Bohm; Mahdi Ghani; Christiane Reitz; Dolly Reyes-Dumeyer; Yufeng Shen; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux
Journal:  Ann Neurol       Date:  2015-02       Impact factor: 10.422

6.  Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors.

Authors:  Robert A Stull; Roya Tavassoli; Scot Kennedy; Steve Osborn; Rachel Harte; Yan Lu; Cheryl Napier; Arie Abo; Daniel J Chin
Journal:  BMC Genomics       Date:  2005-04-18       Impact factor: 3.969

7.  Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates.

Authors:  Andrew C Nyborg; Thomas B Ladd; Craig W Zwizinski; James J Lah; Todd E Golde
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.